SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):18P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Souvatzoglou, M.
Right arrow Articles by Reske, S.
PubMed
Right arrow Articles by Souvatzoglou, M.
Right arrow Articles by Reske, S.

Oncology-Clinical Diagnosis: Solid Tumors

Breast Cancer

PET/CT for restaging breast cancer – Impact on patient management and patient outcome

Michael Souvatzoglou1, Andreas Buck1, Stefan Schmidt2, Stefan Quante1, Ken Herrmann1, Klemens Scheidhauer1, G. Glatting3, S. Pauls3, Markus Schwaiger1 and Sven Reske3

1 Nuclear Medicine; 2 Radiology, TU Muenchen, Muenchen, Germany; 3 Nuclear Medicine, University of Ulm, Ulm, Germany

72

Objectives: The purpose of this study was to assess the diagnostic effectiveness of PET/CT for restaging breast cancer. Furthermore, impact on patient management and patient outcome was evaluated.

Methods: In this prospective bi-center trial, 118 patients with a history of breast cancer and newly diagnosed increase of tumor markers or other clinical signs for recurrent disease were included. 60-90 min after iv-injection of FDG, pts underwent PET/CT imaging (PET 3min/bp, i.v. contrast diagnostic CT) using PET/CT scanners. Each PET/CT mode was evaluated seperately by two physicians blinded to other modalities’ results using a 5-point score. A consensus for final lesion characterisation was made for PET/CT. Follow up data are available in 87/118 pts. Imaging results were correlated to patient management and patient outcome (Logrank test).

Results: PET/CT returned positive findings in 67% (79/118). Local recurrent breast cancer was observed in 14 pts (12%), metastases in lymph nodes in 42 (36%), in the lungs in 12 (10%), in pleura in 2 (2%), in liver in 17 (14%), in bone in 38 (32%) and in the adrenals in 4 pts (3%). PET negative lesions were found in 10% (12/118). So far there was a change of therapeutic management in 29/87 pts (33%). Furthermore, after mean follow-up of 3 years, in PET/CT negative pts median survival was not reached (>90% survivors), while in pts with a positive PET/CT scan, median survival was 3.3 years (p=0.013).

Conclusions: In pts with breast cancer suspicious for having recurrent disease, PET/CT detected local or distant recurrence in 67% and had a major impact on patient management. Our study also shows the prognostic potential of PET/CT for restaging breast cancer.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Souvatzoglou, M.
Right arrow Articles by Reske, S.
PubMed
Right arrow Articles by Souvatzoglou, M.
Right arrow Articles by Reske, S.